Psoriasis


e-Poster Hall
English
e-Poster
09 October 2019 00:00 - 00:00


Presentations

P1580 Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab
MD Bo Ri Kim
09 October 2019 00:00 - 00:00

P1582 Dynamics of the level of some indicators of inflammation regulation in blood of patients with psoriatic arthritis during the complex treatment course
Dr. PhD Oleksandra Havryliuk
09 October 2019 00:00 - 00:00

P1583 Evaluation of metal ions content in blood serum, erythrocytes and urine of patients with psoriasis associated with arterial hypertension
Dr. PhD Oleksandra Havryliuk
09 October 2019 00:00 - 00:00

P1584 Association of non-alcoholic fatty liver disease severity and severity of psoriasis
Assoc. Prof. Rezvan Talaee
09 October 2019 00:00 - 00:00

P1585 Fumaric acid ester-induced T cell lymphopenia: implications for long-term management of psoriasis
PD Dr. med. Heinrich Dickel
09 October 2019 00:00 - 00:00

P1586 SEVERE NAIL PSORIASIS MANAGED SUCCESFULLY WITH APREMILAST
Dr. Alicia Lapresta
09 October 2019 00:00 - 00:00

P1587 Efficacy and safety of calcipotriol plus betamethasone diproprionate cutaneous aerosol foam treatment for psoriasis in patients with body surface area 5–15% and Physician's global assessment >/=3
Prof. Lars Iversen
09 October 2019 00:00 - 00:00

P1588 Gender Differences in the Impact of Psoriasis: Results from the World Psoriasis Happiness Surveys
Sandy McBride
09 October 2019 00:00 - 00:00

P1589 Clinical Efficacy of Secukinumab vs Ustekinumab: 52-Week Treat-to-Target Endpoints in CLEAR, a Randomized Controlled Trial of Patients With Moderate to Severe Psoriasis
MD April W. Armstrong
09 October 2019 00:00 - 00:00

P1590 Patient reported outcomes among patients with psoriasis who initiated guselkumab in a large North American psoriasis registry
Kristina Callis-Duffin
09 October 2019 00:00 - 00:00

P1592 Ustekinumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Pediatric Patients (>= 6 to <12 year of age): Pharmacokinetics and Immunogenicity Results From CADMUS Jr
Dr. Yaowei Zhu
09 October 2019 00:00 - 00:00

P1594 Consistency of Response by age in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab vs. Secukinumab: Week 48 Results From the ECLIPSE Study Trial
Dr. April Armstrong
09 October 2019 00:00 - 00:00

P1597 Demographics and disease characteristics of patients with psoriasis who initiated guselkumab in a large North American psoriasis registry
Kristina Callis-Duffin
09 October 2019 00:00 - 00:00

P1598 Lack of ECG effects of BMS-986165, an oral, selective tyrosine kinase 2 (TYK2) inhibitor: results from a thorough QT study in healthy subjects
Dr. Ihab Girgis
09 October 2019 00:00 - 00:00

P1599 Palmoplantar pustulosis with pyoderma gangrenosum with Behcet’s disease: A triple whammy!!
MD Sayli Korde
09 October 2019 00:00 - 00:00

P1600 Efficacy of secukinumab in Chinese moderate-to-severe psoriasis patients: Results from the CAIN457A2318 study
Prof. Jian-Zhong Zhang , Beijing - China
09 October 2019 00:00 - 00:00

P1601 Comparing the expression profile of TGFB1-3 and the value of clinical advancement indicators of psoriasis during cyclosporin A therapy dependant on the co-occurence of the metabolic syndrom.
Assoc. Prof. Dominika Wcislo-Dziadecka
09 October 2019 00:00 - 00:00

P1602 Patient reported outcomes during treatment in patients with moderate-to-severe psoriasis
MD Nikolai Dyrberg Loft
09 October 2019 00:00 - 00:00

P1603 Effect of tofacitinib on cardiovascular events in patinets with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials
Dr. Wenhui Xie
09 October 2019 00:00 - 00:00

P1604 Association between tofacitinib-based therapy and cardiovascular events in patients with chronic plaque psoriasis
Dr. Wenhui Xie
09 October 2019 00:00 - 00:00

P1605 A look at patient profiles, drug persistence and safety of ustekinumab use in Greece: Data from the "Calipso" study
Prof. Dr. Dimitrios Ioannides
09 October 2019 00:00 - 00:00

P1607 Our experience with apremilast treatment
MD Maria Gazdikova
09 October 2019 00:00 - 00:00

P1609 Apremilast as a Treatment Option for Palmoplantar Pustular Psoriasis?
Prof. Dr. Gudrun Ratzinger
09 October 2019 00:00 - 00:00

P1611 Treatment Satisfaction in Patients With Plaque Psoriasis Initiating Secukinumab in Clinical Practice: Results From US Dermatology Electronic Medical Records
MD, PhD Paul Yamauchi , Santa Monica - United States
09 October 2019 00:00 - 00:00

P1612 Efficacy and safety of guselkumab in the treatment of moderate-to-severe plaque psoriasis in real-world clinical practice
Matthew Ladda
09 October 2019 00:00 - 00:00

P1613 Elucidating the role of innate immunity involving IL-1 cytokines and inflammasone signaling pathways in the pathogenesis of plaque psoriasis
Dr. Sophie Carrie Shan Cai
09 October 2019 00:00 - 00:00

P1614 Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in Chinese patients with psoriasis subtypes
Dr. Wen-Ming Wang
09 October 2019 00:00 - 00:00

P1615 Optimal quality of life improvement in pediatric psoriasis is reached with PASI response >90% or BSA decrease >90% and systemic treatments.
MD Finola Bruins
09 October 2019 00:00 - 00:00

P1616 A case of coexisting palmoplantar pustulosis and eosinophilic pustular folliculitis with en coup de sabre
Dr. Po-Han Ho
09 October 2019 00:00 - 00:00

P1617 Efficacy of Certolizumab Pegol for Psoriasis of the Head and Neck in Two Phase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2
Peter van de Kerkhof
09 October 2019 00:00 - 00:00

P1618 Secukinumab Maintains Superiority Over Ustekinumab in Clearing Skin and Improving Quality of Life in Patients With Moderate to Severe Plaque Psoriasis: 52-Week Results From CLARITY
Jennifer Thurmon
09 October 2019 00:00 - 00:00

P1620 Treatment Expectations and Burden of Under-treatment in Moderate to Severe Psoriasis Patients: Results of a US Web-based Survey
Joseph Gorelick
09 October 2019 00:00 - 00:00

P1621 An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study
Prof. Dr. Diamant Thaçi , Lubeck - Germany
09 October 2019 00:00 - 00:00

P1622 Evaluation of Serum Clusterin Levels in Patients with Psoriasis Vulgaris 
MD Esra Ari
09 October 2019 00:00 - 00:00

P1623 Expert group consensus on the management of cardiovascular comorbidities in patients with moderate-to-severe psoriasis and psoriatic arthritis
Dr. Jose Luis Lopez-Estebaranz , Madrid - Spain
09 October 2019 00:00 - 00:00

P1624 Possibilities of eHelath devices for psoriasis patients to improve patients care.
Lena Domogalla
09 October 2019 00:00 - 00:00

P1625 PSO-LONG: use of the psoriasis symptom inventory in a Phase 3 trial studying the long-term efficacy and safety of fixed-dose combination calcipotriol 0.005% and betamethasone diproprionate 0.064% foam in patients with psoriasis
Dr. Mark Lebwohl , New York - United States
09 October 2019 00:00 - 00:00

P1626 Dose optimization of brodalumab in moderate-to-severe plaque psoriasis
Matthew Ladda
09 October 2019 00:00 - 00:00

P1627 Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs betamethasone dipropionate/calcipotriol foam in plaque psoriasis
Dr. Oriol Yelamos Pena , New York - Spain
09 October 2019 00:00 - 00:00

P1629 Prospective controlled pilot study analysing the value of an educational program and a psoriasis app for psoriasis patients.
Theresa Schulze-Hagen
09 October 2019 00:00 - 00:00

P1631 Guselkumab Demonstrates Greater Efficacy Compared to Secukinumab Across Body Weight Quartiles and Body Mass Index Categories: Week 48 Results From the ECLIPSE Trial
Dr. April Armstrong
09 October 2019 00:00 - 00:00

P1632 Secukinumab Treatment Led to Normalization of Quality of Life and Disease Symptoms in Psoriasis Patients with or without Prior Systemic Psoriasis Therapy: PROSE Study Results
Prof. Matthias Augustin
09 October 2019 00:00 - 00:00

P1633

Analysis of dermatologic endpoints from two Phase 3 studies of tofacitinib in patients with psoriatic arthritis


Dr. Joseph F. Merola
09 October 2019 00:00 - 00:00

P1634 Consistency of Response by Disease Severity Characteristics in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab vs. Secukinumab: Week 48 Results From ECLIPSE Study
Prof. Richard Langley , Nova Scotia - Canada
09 October 2019 00:00 - 00:00

P1635 Efficacy of Guselkumab Versus Secukinumab in Patients With Moderate-to-Severe Plaque Psoriasis in Subgroups Defined by Previous Psoriasis Medication History: Results From the ECLIPSE Study
Dr. Andrew Blauvelt , Portland - United States
09 October 2019 00:00 - 00:00

P1636 Guselkumab is the favorable initial treatment option in patients with moderate-to-severe plaque psoriasis naive to systemic treatment and is also effective after switch from FAE to guselkumab
Dr. PhD Stefanie Krampe
09 October 2019 00:00 - 00:00

P1637 The 64-week safety profile of guselkumab is favorable compared to fumaric acid esters in psoriasis patients - long term safety results from the German POLARIS trial
Dr. PhD Stefanie Krampe
09 October 2019 00:00 - 00:00

P1638 Guselkumab is superior compared to fumaric acid esters in improving the quality of life of systemic naive and FAE pre-treated psoriasis patients - week 56 results from the POLARIS trial
Dr. PhD Stefanie Krampe
09 October 2019 00:00 - 00:00

P1639 Physician- and Patient-Reported Outcomes With Apremilast in Patients With Plaque Psoriasis in Belgium: An Interim Analysis of the OTELO Study
Pierre-Dominique Ghislain
09 October 2019 00:00 - 00:00

P1640 Understanding the Burden of Moderate Psoriasis: The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
Mark Lebwohl
09 October 2019 00:00 - 00:00

P1641 Interim Results of a Nationwide, Real-World Prospective Study of the Therapeutic Effects of Apremilast on the Quality of Life and Disease Activity Parameters Among Patients With Moderate Psoriasis Treated in Greece [APRAISAL Study]
Μarkos Papakonstantis
09 October 2019 00:00 - 00:00

P1642 Insights from the Apremalist After Switching from Fumaric Acid Ester Treatment (APART) Study: An Interim Real-World Safety Analysis
Ulrich Mrowietz
09 October 2019 00:00 - 00:00

P1643 Rates of Myocardial Infarction, Stroke, and Revascularization Among Patients With Psoriasis Treated With Apremalist, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Rebecca Persson
09 October 2019 00:00 - 00:00

P1644 Efficacy and Safety of Tildrakizumab 100 mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in reSURFACE1
Prof. Wendy Cantrell
09 October 2019 00:00 - 00:00

P1645 Clearance of Head Involvement in Plaque Psoriasis with Tildrakizumab Treatment in the Phase 3 reSURFACE 1 Study
Prof. Alan Menter
09 October 2019 00:00 - 00:00

P1646 Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from reSURFACE 1
Dr. Jeffrey Crowley
09 October 2019 00:00 - 00:00

P1647 Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from reSURFACE 2
Prof. Richard G. Langley
09 October 2019 00:00 - 00:00

P1648 Relationship of Serum Glucose to Efficacy and Safety of Tildrakizumab Treatment for Psoriasis in Patients with and without Metabolic Syndrome from reSURFACE 1 and reSURFACE 2
Dr. Mark Lebwohl
09 October 2019 00:00 - 00:00

P1649 Pharmacokinetics and Immunogenicity of Guselkumab Through up to 3 Years of Therapy in Patients With Moderate-to-Severe Plaque Psoriasis
Dr. Yaowei Zhu
09 October 2019 00:00 - 00:00

P1650 Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 reSURFACE 2 Study
Prof. Alice B Gottlieb
09 October 2019 00:00 - 00:00

P1651 Psoriasis in a patient with generalized morphea. Is it an independent or an associated condition?
MD Uriel Villela-Segura
09 October 2019 00:00 - 00:00

P1652 Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administered every other week in patients with psoriasis at a single Japanese institution
MD, PhD Koji Kamiya
09 October 2019 00:00 - 00:00

P1653 Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 reSURFACE 1 Study
Dr. Mark G Lebwohl
09 October 2019 00:00 - 00:00

P1654 Persistence of Improvement in Sexual Impact Associated with Moderate-to-Severe Genital Psoriasis for up to 52 Weeks of Treatment with Ixekizumab
Caitriona Ryan
09 October 2019 00:00 - 00:00

P1656 Effect of Secukinumab Treatment on Measures of Insulin Resistance in Patients With Psoriasis
MD, PhD James Krueger , New York - United States
09 October 2019 00:00 - 00:00

P1657 Association between psoriasis and cutaneous T-cell lymphoma
MD Ana Mateos Mayo
09 October 2019 00:00 - 00:00

P1658 Sustained High Efficacy and a Favorable Safety Profile in Hard-to-Treat Areas in Patients with Moderate-to-Severe Psoriasis: Five-Year Results from a Phase 3 Trial
MD, PhD Kim A Papp
09 October 2019 00:00 - 00:00

P1659 Rapid Improvement in Clinical Outcomes and Complete Clearance with Ixekizumab versus Etanercept or Ustekinumab: an Analysis of Severe Psoriasis Patients as Stratified by Body Surface Area
MD Howard L Sofen
09 October 2019 00:00 - 00:00

P1660 Ixekizumab achieves rapid and high clearance in psoriasis patients with or without prior exposure to biologics
Andreas Pinter
09 October 2019 00:00 - 00:00

P1664 Study on the therapeutic adherence by patients with psoriasis in France
Dr. Bruno HALIOUA
09 October 2019 00:00 - 00:00

P1665 Patients' perceptions and experiences of biologic therapies for psoriasis in France
Dr. Bruno HALIOUA
09 October 2019 00:00 - 00:00

P1666 Experience with certolizumab pegol in cutaneous psoriasis: description of 3 cases
MD Elena Garcia Zamora
09 October 2019 00:00 - 00:00

P1667 Psoriasis and pregnancy outcomes in biological therapy: a real-life, multi center experience
Dr. Giulia Odorici
09 October 2019 00:00 - 00:00

P1668 Clinical experience of ixekizumab in the treatment of patients with erythrodermic psoriasis who failed secukinumab:  a case series
Dr. Yang Lo
09 October 2019 00:00 - 00:00

P1669 An assessment of treatment efficacy in patients with psoriasis who receive ustekinumab and the potential effect of metabolic syndrome on treatment response
MD Ömer Kutlu
09 October 2019 00:00 - 00:00

P1670 Relationship between the prevalence of cardiovascular disorders and the type of psoriasis in 89 Japanese patients with psoriasis.
Assoc. Prof. Fumikazu Yamazaki
09 October 2019 00:00 - 00:00

P1671

Adiponectin levels in a large pooled plaque psoriasis study population


Dr. Mona Biermann
09 October 2019 00:00 - 00:00

P1672 Cost per responder of calcipotriol plus betamethasone dipropionate foam versus non-biologic systemic therapy for moderate to severe plaque psoriasis in four European countries
Lidia Becla
09 October 2019 00:00 - 00:00

P1674 Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
Kenneth Gordon
09 October 2019 00:00 - 00:00

P1675 Study Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Impact of Apremilast on Quality of Life, Efficacy, and Safety in Patients With Specific Manifestations of Psoriasis and Impaired Quality of Life (EMBRACE)
Michelle Dasaro
09 October 2019 00:00 - 00:00

P1676 Analysis of Patients With Moderate Psoriasis in "Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for the Treatment of Psoriasis" (OBSERVE-5)
Dr. Kim A. Papp , Waterloo - Canada
09 October 2019 00:00 - 00:00

P1677 Assessing the quality and coherence of network meta-analyses of biologics in plaque psoriasis: what does all this evidence synthesis tell us?
Emily Wright
09 October 2019 00:00 - 00:00

P1678 Patient-Related Outcomes in the "Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for the Treatment of Psoriasis" (OBSERVE-5) Population
Dr. Kim A. Papp , Waterloo - Canada
09 October 2019 00:00 - 00:00

P1679 Refractory palmoplantar pustulosis successfully treated with apremilast
MD, PhD Raquel Carrascosa
09 October 2019 00:00 - 00:00

P1680 Absolute Psoriasis Area and Severity Index Improvement in Psoriasis Patients Treated With Guselkumab or Secukinumab: Results From the ECLIPSE Study
Prof. Dr. Kristian Reich , Hamburg - Germany
09 October 2019 00:00 - 00:00

P1681 Biologic treatment in elderly patients with psoriasis: a systematic review
Vijay Sandhu
09 October 2019 00:00 - 00:00

P1682 Apremilast in psoriasis patients with a history of malignancy - case series
Assoc. Prof. Suzana Ozanic Bulic
09 October 2019 00:00 - 00:00

P1683 Optimization of secukinumab in clinical practice
MD Susana Medina
09 October 2019 00:00 - 00:00

P1685 Efficacy and Safety of Certolizumab Pegol in the Treatment of Japanese Patients With Psoriasis: Interim Week 24 Analyses from a 52-Week Phase 2/3, Randomised, Placebo-Controlled Study
Akihiko Asahina
09 October 2019 00:00 - 00:00

P1686 Real-world treatment patterns and efficacy of flexible-dosing etanercept in patients with plaque psoriasis in Greece
Prof. Christina Antoniou
09 October 2019 00:00 - 00:00

P1687 Efficacy and safety of switching from originator infliximab to biosimilar in patients with chronic plaque psoriasis; a Greek case study
Dr. med. Aristea Stravodimou
09 October 2019 00:00 - 00:00

P1688 The role of dermal fibroblasts in supporting immune-homeostasis and its inhibition by IL-17
Adriana Rendon
09 October 2019 00:00 - 00:00

P1689 Effectiveness and safety of secukinumab in a real-world clinical setting in Europe: 1-year results from an interim analysis of the SERENA study
Prof. Dr. Matthias Augustin , Hamburg - Germany
09 October 2019 00:00 - 00:00

P1690 Real-World-Evidence: Efficacy and tolerability of a topical formulation containing Urea, Ceramides, Glucoglycerol an Natural Moisturizing Factors (NMF´s) in the treatment of Psoriasis.
Anne-Christin Worthmann
09 October 2019 00:00 - 00:00

P1691 Effect of Metabolic Syndrome on Efficacy and Safety in Patients With Psoriasis Treated With Etanercept or Tildrakizumab: Post Hoc Analysis of 2 Phase 3 Clinical Studies (reSURFACE 1 and reSURFACE 2)
Alice Gottlieb
09 October 2019 00:00 - 00:00

P1692 Tildrakizumab provides early predictability of response in patients with moderate-to-severe psoriasis: results from reSURFACE 1 and reSURFACE 2 phase 3 trials
Prof. Richard Warren , Manchester - United Kingdom
09 October 2019 00:00 - 00:00

P1693

Natural Phototherapy of Psoriasis at the Dead Sea in Jordan


Dr. Zuhair Zahi Bisharat
09 October 2019 00:00 - 00:00

P1694 Long-term Efficacy and Safety of Brodalumab Through 120 Weeks and After Withdrawal and Retreatment
Prof. Craig Leonardi , St. Louis - United States
09 October 2019 00:00 - 00:00

P1695 Biologic therapies and apremilast for patients with moderate to severe psoriasis: a systematic review and network meta-analysis of 52-week PASI response
Eydna Apol
09 October 2019 00:00 - 00:00

P1696 Consistent Responses to Guselkumab by Geographic Region at Week 48 in the Treatment of Moderate to Severe Psoriasis: Results From the ECLIPSE Trial
Prof. Dr. Kristian Reich , Hamburg - Germany
09 October 2019 00:00 - 00:00

P1697 Time to relapse in patients with moderate-to-severe psoriasis who were tildrakizumab responders at week 28: post-hoc analysis through 64 weeks from reSURFACE 1 trial.
Prof. Dr. Kristian Reich , Hamburg - Germany
09 October 2019 00:00 - 00:00

P1698 Nail psoriasis severity associated with psoriatic arthritis and quality life disorders: data from a single dermatological setting.
MD, PhD Maria Chamurlieva
09 October 2019 00:00 - 00:00

P1699

Patients with Psoriasis are still immensely undertreated: Results from the DERMLINE online survey


Dr. Elena Hacker
09 October 2019 00:00 - 00:00

P1700

Characterization of different psoriatic disease phenotypes based on pooled data from the extensive secukinumab phase 3 program


Prof. Dr. Kristian Reich , Hamburg - Germany
09 October 2019 00:00 - 00:00

P1701 Real-World Efficacy of Apremilast in Patients With Psoriasis With and Without Comorbid Psoriatic Arthritis: Findings From the Corrona Psoriasis Registry
Michelle Dasaro
09 October 2019 00:00 - 00:00

P1702 Characteristics of Psoriasis Patients and Use of Apremilast Classified by Psoriasis Severity and Disease Burden: Results From the Corrona Psoriasis Registry
Michelle Dasaro
09 October 2019 00:00 - 00:00

P1703 Apremilast Real-World Treatment Outcomes in Psoriasis Patients With Comorbid Psoriatic Arthritis: An Analysis of the APPRECIATE Study
Michelle Dasaro
09 October 2019 00:00 - 00:00

P1704 Efficacy of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Subgroup Analysis of Results From a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study
Michelle Dasaro
09 October 2019 00:00 - 00:00

P1705 Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: 32-Week Results From the Phase 3, STYLE Study
Michelle Dasaro
09 October 2019 00:00 - 00:00

P1706 12-week secukinumab treatment is consistently efficacious in moderate-to-severe psoriasis patients regardless of prior treatment with systemics, including conventional systemics, based on post-hoc analysis
Dr. Philip Hampton
09 October 2019 00:00 - 00:00

P1707 Multidisciplinary consultation in psoriasis: Dermatology and Internal Medicine
MD Ana Julia Garcia Malinis
09 October 2019 00:00 - 00:00

P1708 Evaluation of demographic and clinical characteristics of psoriatic patients based on body mass index and waist circumference
Prof. Rebiay Kiran
09 October 2019 00:00 - 00:00

P1709 PSID – Psoriatic arthritis manifestation Screening to Identify early Disease stages in German psoriasis patients
Dr. med. Phillip Barteczek
09 October 2019 00:00 - 00:00

P1710 Improvement of patient-reported outcomes in patients with moderate-to-severe plaque psoriasis on dimethyl fumarate treatment: interim analysis through 24 weeks from DIMESKIN 1 study
Dr. Jose-Manuel Carrascosa , Rubì-Barcelona - Spain
09 October 2019 00:00 - 00:00

P1711 Results of Certolizumab pegol efficacy on Psoriasis Vulgaris
Dr. Annunziata Dattola
09 October 2019 00:00 - 00:00

P1712 Efficacy of dimethyl fumarate in clinical practice among patients with moderate-to-severe plaque psoriasis: interim analysis through 24 weeks from DIMESKIN 1 study.
Dr. Jose-Manuel Carrascosa , Rubì-Barcelona - Spain
09 October 2019 00:00 - 00:00

P1713 Long-term Efficacy and Safety of Switching from Adalimumab to Risankizumab: Results from the Open-Label Extension LIMMitless
Prof. Dr. Kristian Reich , Hamburg - Germany
09 October 2019 00:00 - 00:00

P1714 Long-term Efficacy and Safety of Switching from Ustekinumab to Risankizumab: Results from the Open-Label Extension LIMMitless
Dr. Bruce Strober
09 October 2019 00:00 - 00:00

P1715 Impact of Body-Weight on the Efficacy and Exposure-Response of Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase 3 Clinical Trials
Dr. Craig Leonardi
09 October 2019 00:00 - 00:00

P1716 Comparison of Dermatology Quality of Life Index for Novel Treatments of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis
Prof. Richard Warren , Manchester - United Kingdom
09 October 2019 00:00 - 00:00

P1718 Complement Factor H as a potential biomarker for disease severity and clinical response to treatment in psoriasis
Dr. Miguel Alpalhão
09 October 2019 00:00 - 00:00

P1719 Skin shame is related to reduced mental and physical quality of life in psoriasis patients
Dr. med. donja homayoon
09 October 2019 00:00 - 00:00

P1721 Epidermal microflora  in patients with psoriasis
Assoc. prof Hennadiy Astsaturov
09 October 2019 00:00 - 00:00

P1722 Some questions about psoriasis  immunopathogenesis
Assoc. prof Hennadiy Astsaturov
09 October 2019 00:00 - 00:00

P1723 New targets in psoriasis therapy
PhD Iryna Voznyak
09 October 2019 00:00 - 00:00

P1724 Our clinical experience with a new anti IL-23 biological drug
Dr. med. Antonio Carpentieri
09 October 2019 00:00 - 00:00

P1725 Ustekinumab improves patient-reported outcomes, including DLQI and psoriasis symptoms and signs in a German real-life setting: one year-results from the PERSIST study
Dr. med. Sven Wegner
09 October 2019 00:00 - 00:00

P1726 Effectiveness of interleukin-17A antagonists for generalized  pustular psoriasis in six Japanese patients
Dr. PhD Maiko Kato
09 October 2019 00:00 - 00:00

P1727 Ustekinumab is effective on region-specific psoriasis in a real world setting: one-year results from the PERSIST study
Dr. med. Sven Wegner
09 October 2019 00:00 - 00:00

P1728 Clinical Experience switching from IL12/23 to IL-17 blockade in patients with plaque psoriasis
Dr. Alejandro Molina-Leyva
09 October 2019 00:00 - 00:00

P1729 Real world experience on clinical utility of apremilast in patients with plaque psoriasis in kolkata in India
Dr. Dhiraj Dhoot
09 October 2019 00:00 - 00:00

P1730 Successful treatment of inverse psoriasis with brodalumab: a case report
Dr. Efstratios Vakirlis
09 October 2019 00:00 - 00:00

P1731 Long-term safety of tildrakizumab in patients 65 years of age or older with moderate-to-severe psoriasis: pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials.
Prof. Dr. Peter C.M. Van de Kerkhof , Nijmegen - Netherlands
09 October 2019 00:00 - 00:00

P1732 Efficacy and safety of calcipotriol plus betamethasone dipropionate cutaneous foam in treating scalp psoriasis: a review of data from two phase 2 studies
Dr. Mark Lebwohl , New York - United States
09 October 2019 00:00 - 00:00

P1733 No evidence for interactions of dimethylfumarate and its main metabolite monomethylfumarate with human cytochrome P450 enzymes and the P-glycoprotein transport system
Jordi Aubets
09 October 2019 00:00 - 00:00

P1734 Topology of psoriasis in sexually sensitive and visible body areas: Disease burden and patient needs in routine care
Dr. Neuza da Silva
09 October 2019 00:00 - 00:00

P1735 Analysis of the Psoriasis Health Care Survey in 16 Latin American countries (pilot study) - the Global Psoriasis Atlas
Prof. Dr. Matthias Augustin , Hamburg - Germany
09 October 2019 00:00 - 00:00

P1736 Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate-to-severe plaque psoriasis: 60-week results from a randomised, double-blinded, Phase 2b extension study
Ann-Marie Shaw
09 October 2019 00:00 - 00:00

P1737 Safety of Tildrakizumab in Patients With Preexisting Metabolic Syndrome: Long-Term Data From the Post Hoc Analysis of 2 Phase 3 Clinical Trials (reSURFACE 1 and reSURFACE 2)
Craig Leonardi
09 October 2019 00:00 - 00:00

P1738 Secukinumab, the Hospital 12 de Octubre experience (five years of practice and beyond)
Dr. Juan José Andrés-Lencina
09 October 2019 00:00 - 00:00

P1739 The effect of alexithymia, rumination and coping style on exacerbation of the disease in psoriasis.
Dr. Sevim Baysak
09 October 2019 00:00 - 00:00

P1740 Methotrexate usage trends in psoriasis in a tertiary care hospital _ a retrospective study
Prof. Sankarasubramanian Anandan , Porur, Chennai - India
09 October 2019 00:00 - 00:00

P1741 Real-World Treatment Effect of Adalimumab on Patient Reported Outcomes in Moderate-to-Severe Psoriasis - Results from the EQUIPE Study
Evgeniya Hristakieva
09 October 2019 00:00 - 00:00

P1743 The adalimumab biosimilar BCD-057 vs. innovator adalimumab in patients with moderate-to-severe plaque psoriasis: 55-week results from Phase 3/CALYPSO study
MD, PhD Vladislav Khairutdinov
09 October 2019 00:00 - 00:00

P1744 Psoriasis vulgaris in association with vitiligo
Dr. Katerina Stoyanova
09 October 2019 00:00 - 00:00

P1745 Phenotypic and genetic associations of body mass index with psoriasisi
Prof. Dr. Vladimir Vasku , Brno - Czech Republic
09 October 2019 00:00 - 00:00

P1746 Patients' acceptability of using electronic health records in the treatment of posoriasis
Toni Maria Klein
09 October 2019 00:00 - 00:00

P1747 Patients' attitudes and expectations towards electronic health records in the treatment of psoriasis
Toni Maria Klein
09 October 2019 00:00 - 00:00

P1748 Physicians' acceptability of electronic health records in the treatment of psoriasis
Toni Maria Klein
09 October 2019 00:00 - 00:00

P1749 Absolute and relative PASI treatment goals and their correlation with DLQI
PD Dr. med. Andreas Körber
09 October 2019 00:00 - 00:00

P1751 Optical Coherence Tomography (OCT) capillaroscopy of nail psoriasis - a feasibility study comparing OCT, nailfold capillaroscopy, MRI and ultrasound of affected digits
MD Jørgen Guldberg-Møller
09 October 2019 00:00 - 00:00

P1752 Tolerance of an emollient balm dedicated to psoriasis skin in patients with plaque psoriasis treated by topical, oral treatment or phototherapy.
MD Marie-Dominique THOUVENIN
09 October 2019 00:00 - 00:00

P1753 Real-world single-center experience with ten cases of generalized pustular psoriasis successfully treated with ixekizumab and its impact on circulating interleukin-22
MD Mayumi Nagata
09 October 2019 00:00 - 00:00

P1754 Efficacy of tildrakizumab in patients with moderate-to-severe psoriasis according to disease duration: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28
Prof. Dr. Diamant Thaçi , Lubeck - Germany
09 October 2019 00:00 - 00:00

P1755 A case of generalized pustular psoriasis with coexisting mutations in IL-36RN and CARD14
MD Yukiko Sawabe
09 October 2019 00:00 - 00:00

P1756 Psoriasis severity is related to the severity of non-alcoholic fatty liver disease
Dr. Daniel Nieto
09 October 2019 00:00 - 00:00

P1757 Guselkumab in the treatment of patients affected by moderate- severe plaque psoriasis: real-word evidence
Dr. Marina Talamonti
09 October 2019 00:00 - 00:00

P1758 Generalized and palmoplantar pustular psoriasis and acrodermatitis continua of Hallopeau: a case series of 8 patients treated with apremilast
MD Raquel Aragón-Miguel
09 October 2019 00:00 - 00:00

P1759 Effectiveness of cyclosporine in patients with moderate-severe plaque type psoriasis in a real life clinical setting: TRANSITION study
Elisabetta Aloisi
09 October 2019 00:00 - 00:00

P1760 Psoriasis vulgaris and bullous pemphigoid - managment of two cases
Dr. Gabriela Dzhelyatova
09 October 2019 00:00 - 00:00

P1761 Secukinumab improves anxiety and depression in patients with moderate-to-severe psoriasis: results from the SUPREME study
Elisabetta Aloisi
09 October 2019 00:00 - 00:00

P1762 Sociodemographic and Baseline Disease Profile of Patients with Moderate-to-severe Chronic Plaque Psoriasis Treated with Secukinumab vs. Other Treatments: 30 months update from the PURE Registry
Kim. A Papp
09 October 2019 00:00 - 00:00

P1763 Secukinumab treated Patients in the PURE Registry (Patients with moderate-to-severe chronic plaqUe psoRiasis in Latin AmErica and Canada): 30-month Follow-up Data
Kim. A. Papp
09 October 2019 00:00 - 00:00

P1764 Safety of Risankizumab in Patients With Moderate-to-Severe Psoriasis: Analysis of Pooled Clinical Trial Data
Prof. Herve Bachelez
09 October 2019 00:00 - 00:00

P1765 Efficacy of ixekizumab versus adalimumab in psoriatic arthritis patients with moderate-to-severe psoriasis: 24-weeks results from a multicentre, randomised study
Prof. Dr. Kristian Reich , Hamburg - Germany
09 October 2019 00:00 - 00:00

P1767 Validity of weight self-report in patients with psoriasis.
Dr. PhD Filip Rob , Prague - Czech Republic
09 October 2019 00:00 - 00:00

P1768 Clinical characteristics of inverse psoriasis
Dr. Emese Varga
09 October 2019 00:00 - 00:00

P1769 Koebner phenomenon induced by a computer mouse: a rare etiology for a common phenomenon
Dr. Miguel Alpalhão
09 October 2019 00:00 - 00:00

P1770 Clinical and Treatment Differences in Psoriasis Patients of Racial Minorities
Dr. Mathew Nicholas
09 October 2019 00:00 - 00:00

P1771 Psoriasis and metabolic syndrom in children: A case control study
Dr. Marouane Ben Kahla
09 October 2019 00:00 - 00:00

P1772 Factors predicting pruritus in psoriasis
MD Siham Mansouri
09 October 2019 00:00 - 00:00

P1773

Early Improvements in Plaque Psoriasis Clinical Response with Fixed-Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam Treatment from the PSO-FAST Trial


PhD Karen A. Veverka
09 October 2019 00:00 - 00:00

P1774 Subcorneal pustular dermatosis and acrodermatitis continua of Hallopeau: clinical spectrum of the same disorder?
MD Tatiana Mina Yendo
09 October 2019 00:00 - 00:00

P1775 Decreased expression of response gene to complement 32 in psoriasis
Prof. Dr. Jooyoung Roh
09 October 2019 00:00 - 00:00

P1776

Duration of Response – Application of Adjusted Kaplan-Meier Curves Comparing Ixekizumab and Ustekinumab


Dr. Marc Radtke
09 October 2019 00:00 - 00:00

P1777 Associations between blood pressure, body mass index and quality of life with severity of psoriasis
MD Fitria Salim
09 October 2019 00:00 - 00:00

P1778 Efficacy and safety of Ixekizumab in patients with moderate to severe psoriasis resistant to anti-TNF or anti-IL
Dr. Gustavo Guillermo Garriga MArtina
09 October 2019 00:00 - 00:00

P1779 Tolerance and efficacy of a new dermo-cosmetic care product dedicated to body plaque and scalp psoriasis.
MD Marie-Dominique THOUVENIN
09 October 2019 00:00 - 00:00

P1780 Definition of psoriasis severity in routine care: current guidelines fail to capture the complexity of long-term psoriasis management
Prof. Dr. Matthias Augustin
09 October 2019 00:00 - 00:00

P1781

Tolerance and efficacy of a new dermo-cosmetic shampoo dedicated to scalp psoriasis.


MD Marie-Dominique THOUVENIN
09 October 2019 00:00 - 00:00

P1782 Celastrol enriched plant cell culture extract (CEE) inhibits Th17 pathway in in vitro and ex vivo models of psoriasis
PhD Thien Nguyen
09 October 2019 00:00 - 00:00

P1783 Secukinumab provides sustained improvement in signs and symptoms of psoriatic arthritis in patients with and without enthesitis: 2 year pooled analysis of two Phase 3 studies 
Dr. Johan K Wallman
09 October 2019 00:00 - 00:00

P1784 Association between psoriasis and autoimmune inflammatory comorbidities in Danish women: a nationwide cross-sectional study
MD Caecilie Johansen
09 October 2019 00:00 - 00:00

P1785 Describing real-world psoriasis treatment patterns in the United Kingdom and United States
Dr. Rebecca Batchelor
09 October 2019 00:00 - 00:00

P1786 Secukinumab 150mg in psoriasis: does it work?
Dr. Silvia Herrera
09 October 2019 00:00 - 00:00

P1787 Quality of life in patients with moderate to severe psoriasis treated with methotrexate in routine clinical practice in Spain: FirST Study
Dr. Raquel Rivera
09 October 2019 00:00 - 00:00

P1788 Results from a long-term, observational, non-interventional, prospective study in patients with body psoriasis based on patient-reported outcomes and physician's assessments (BODYGUARD).
Andrey L Bakulev
09 October 2019 00:00 - 00:00

P1789 Considerable variation among Iranian dermatologist in the use of biologic drugs in the treatment of psoriasis
Dr. Reza Mahmoud Robati
09 October 2019 00:00 - 00:00

P1790 Secukinumab real-world effectiveness and safety data on plaque psoriasis treatment in Germany from 2,502 patients: Final results of the PROSPECT study.
Diamant Thaci
09 October 2019 00:00 - 00:00

P1791 Dose escalation of targeted immunomodulator treatment in patients with moderate to severe psoriasis
Dr. Jeffrey Sobell
09 October 2019 00:00 - 00:00

P1792 Subcutaneous MTX in patients with moderate psoriasis
Christina Sorbe
09 October 2019 00:00 - 00:00

P1793 Assessment of changes in originator and biosimilar etanercept prescribing patterns between 2016 and 2018 in Psoriasis in Europe
Dr. Yao Lu
09 October 2019 00:00 - 00:00

P1794 PsoBest: Current status, profiles, impact for health care of the German National Registry on Psoriasis
Diamant Thaci
09 October 2019 00:00 - 00:00

P1795 Complete response of an oral retinoids resistant plantar psorasis with bethametasone patches
MD Antonio Martinez Lopez
09 October 2019 00:00 - 00:00

P1796 Reasons for drug discontinuation among patients in the Corrona Psoriasis Registry
Dr. Bruce Strober , Farmington - United States
09 October 2019 00:00 - 00:00

P1797 A single-center clinical experience with secukinumab in patients with psoriasis. What have we learned?
Dr. Pilar Luque Varela
09 October 2019 00:00 - 00:00

P1799 The patient's journey through the landscape of Psoriasis care - Data from the European study "PsoBarrier EU"
Nicole Zander
09 October 2019 00:00 - 00:00

P1800 PROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY TO CORRELATE NAIL PSORIASIS AND/OR MODERATE TO SEVERE PSORIASIS IN SCALP AND INTERGLUTEAL REGION, WITH ENTHESITIS AND/OR SYNOVITIS, IN PATIENTS WITHOUT CLINICAL ARTHRITIS, BY IMAGING TECHNIQUES (MRI)
MD Dimitra Alifakioti
09 October 2019 00:00 - 00:00

P1802 Effectiveness of secukinumab at 18 months in Canadian psoriasis patients in a real-world setting
Sophie Parent
09 October 2019 00:00 - 00:00

P1803 Psoriatic patients with concurrent arthritis present a subclinical inflammation of respiratory airways
Dr. Giovanni Damiani
09 October 2019 00:00 - 00:00

P1804 Erytrodermic psoriasis treated with secukinumab: a multi center study focusing on addictions impact
Dr. Giovanni Damiani
09 October 2019 00:00 - 00:00

P1805 Optimal control of psoriasis in clinical practice.
Daniel Lopez-Castillo
09 October 2019 00:00 - 00:00

P1806 Docetaxel induced psoriasis
MD Leila Zenjari
09 October 2019 00:00 - 00:00

P1807 Switching from SB4 to ixekizumab: a single institution, prospective cohort study in patients that previously responded to the originator but not to its biosimilar.
Dr. Giovanni Damiani
09 October 2019 00:00 - 00:00

P1808 A prospective multi-center study assessing effectiveness and safety of secukinumab in real-life setting in 171 patients 
MD Lourdes Rodriguez Fernandez-Freire
09 October 2019 00:00 - 00:00

P1809 Serum Homocysteine, Vitamin B12 and Folate Levels in Psoriasis Patients
Dr. Eliza Salijuma
09 October 2019 00:00 - 00:00

P1810 Ramadan fasting as a dietary strategy in psoriatic patients
Dr. Giovanni Damiani
09 October 2019 00:00 - 00:00

P1811 Rheumatoid arthritis and paradoxical psoriasis controlled by apremilast-tocilizumab association
Dr. Iuliana Elena Nita
09 October 2019 00:00 - 00:00

P1812 Diagnosis and management of psoriasis at the Psoriasis clinic in a tertiary academic hospital in Greece
Dr. Eleni Theodorakopoulou
09 October 2019 00:00 - 00:00

P1813 Real-world data for evaluating effectiveness and safety of secukinumab in a single-center of Spain
Dr. MARIA DAÑINO GARCIA
09 October 2019 00:00 - 00:00

P1814 Experience with Apremilast for the treatment of psoriasis in real-world clinical practice
MD Jorge Magdaleno
09 October 2019 00:00 - 00:00

P1815 Sex-related impairments and patient needs in anogenital psoriasis: Difficult to communicate topics and their impact on patient-centred care
Dr. Neuza da Silva
09 October 2019 00:00 - 00:00

P1816 Prospective randomized controlled trial to compare the efficacy of subcutaneous etarnacept versus oral methotrexate in moderate to severe chronic plaque psoriasis and to correlate response with Th1, Th2, Th17 and Treg cell patterns
Dr. Aashim Singh
09 October 2019 00:00 - 00:00

P1817 Psoriasis on a prayer mark: an unusual Koebner phenomenon
MD Olfa Charfi
09 October 2019 00:00 - 00:00

P1818 IL-6 as a potential connection between psoriasis and cerebral palsy - a case report
Dr. Mariya Hadzhiyska
09 October 2019 00:00 - 00:00

P1819 Final Data Set for the Documentation of Psoriasis: a Delphi Approach with Psoriasis Experts
Dr. Marina Otten
09 October 2019 00:00 - 00:00

P1820 Treatment of severe plaque psoriasis with Brodalumab after failure of other biological treatments: 5 cases from real clinical practice
MD Cristian Valenzuela
09 October 2019 00:00 - 00:00

P1821 Psoriatic Nephropathy and Correlation with hs-CRP.
Dr. Ishmeet Kaur
09 October 2019 00:00 - 00:00

P1822 Feasibility and acceptability of using the electronic Patient Benefit Index in practice from patients' perspective
Dr. Marina Otten
09 October 2019 00:00 - 00:00

P1823 The Psoriasis and Psoriatic arthritis clinic model: experience from the first dual clinic in Greece
Dr. Eleni Theodorakopoulou
09 October 2019 00:00 - 00:00

P1824 Reverse prevalence of cardiovascular comorbidities in patients with moderate and severe psoriasis - results of the national care study "PsoHealth4"
Dr. med. Natalie Kirsten , Toulouse - France
09 October 2019 00:00 - 00:00

P1825 Positive effect of better care of moderate to severe Psoriasis on the prevalence of metabolic diseases - results of a German care study "PsoHealth4"
Dr. med. Natalie Kirsten , Toulouse - France
09 October 2019 00:00 - 00:00

P1826 Association of HLA-C gene polymorphism in Indian psoriasis patients
PhD sonam singh
09 October 2019 00:00 - 00:00

P1827 Quality of life in patients with psoriasis: a survey in Italy in 2016-2018
Dr. Ornella De Pità
09 October 2019 00:00 - 00:00

P1828 Impact of palmoplantar psoriasis on quality of life in Georgian population
Prof. Maia Matoshvili
09 October 2019 00:00 - 00:00

P1829 Ustekinumab 90 mg usefulness in real settings. A retrospective, observational multicenter study of 141 patients.
MD Ana Reymundo
09 October 2019 00:00 - 00:00

P1830 Successful response of genital psoriasis to ixekizumab: our clinical experience
MD, PhD Marta de Jesús García-Legaz Martínez
09 October 2019 00:00 - 00:00

P1831 Prevalence of lipid disturbances in patients with psoriasis
MD, PhD Nermina Ovcina-Kurtovic
09 October 2019 00:00 - 00:00

P1832 Biologic Drug Survival in Psoriasis: A Systematic Review and Comparative Meta-Analysis
MD Ahmed Mourad
09 October 2019 00:00 - 00:00